XTRELUS Drug Patent Profile
✉ Email this page to a colleague
When do Xtrelus patents expire, and what generic alternatives are available?
Xtrelus is a drug marketed by Eci Pharms Llc and is included in one NDA.
The generic ingredient in XTRELUS is guaifenesin; hydrocodone bitartrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the guaifenesin; hydrocodone bitartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XTRELUS?
- What are the global sales for XTRELUS?
- What is Average Wholesale Price for XTRELUS?
Summary for XTRELUS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | XTRELUS at DailyMed |
US Patents and Regulatory Information for XTRELUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eci Pharms Llc | XTRELUS | guaifenesin; hydrocodone bitartrate | TABLET;ORAL | 208085-001 | Apr 25, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
